Viatris Lowers 2026 Profit Forecast Amid India Plant Fire
Pharmaceutical company Viatris Inc has projected 2026 profits below analysts’ expectations following a fire at its Nashik manufacturing facility in India. The incident temporarily halted production of tablets and capsules, with operations expected to resume in April. The company has incorporated the disruption into its annual forecast, projecting adjusted per-share profit between $2.33 and $2.47, slightly below the average analyst estimate of $2.49.
The Nashik fire adds pressure to Viatris’ India operations, which have previously faced challenges after the U.S. FDA restricted imports from one of its facilities in December 2024 due to regulatory violations. Viatris, formed from the merger of Mylan and Pfizer’s Upjohn unit in 2020, operates four manufacturing sites in India, including Nashik and Indore, and is planning a global workforce reduction of up to 10% as part of a multi-year restructuring expected to save $600–700 million.
Despite the production setback, Viatris anticipates annual revenue between $14.45 billion and $14.95 billion, slightly above analysts’ estimates. Its branded drugs segment, which includes Viagra, Xanax, Lyrica, and Celebrex, grew 8% in Q4, contributing to total revenue of $3.70 billion for the quarter, up 5% year-on-year. Adjusted quarterly profit came in at 57 cents per share, surpassing the expected 53 cents.
Pic courtesy: google/ images are subject to copyright
